ZA200103524B - Controlled delivery of active agents. - Google Patents

Controlled delivery of active agents. Download PDF

Info

Publication number
ZA200103524B
ZA200103524B ZA200103524A ZA200103524A ZA200103524B ZA 200103524 B ZA200103524 B ZA 200103524B ZA 200103524 A ZA200103524 A ZA 200103524A ZA 200103524 A ZA200103524 A ZA 200103524A ZA 200103524 B ZA200103524 B ZA 200103524B
Authority
ZA
South Africa
Prior art keywords
drug
layer
dosage form
release
wall
Prior art date
Application number
ZA200103524A
Other languages
English (en)
Inventor
Padmanabh Bhatt
Evangeline G Cruz
Noymi Yam
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ZA200103524B publication Critical patent/ZA200103524B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200103524A 1998-11-02 2001-05-02 Controlled delivery of active agents. ZA200103524B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10673998P 1998-11-02 1998-11-02

Publications (1)

Publication Number Publication Date
ZA200103524B true ZA200103524B (en) 2002-05-02

Family

ID=22312996

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200103524A ZA200103524B (en) 1998-11-02 2001-05-02 Controlled delivery of active agents.

Country Status (15)

Country Link
US (3) US6368626B1 (zh)
EP (2) EP1652516A3 (zh)
JP (1) JP2002528486A (zh)
KR (1) KR20010075676A (zh)
CN (1) CN1325301A (zh)
AU (1) AU1238500A (zh)
CA (1) CA2350246C (zh)
HK (1) HK1039456A1 (zh)
HU (1) HUP0104993A3 (zh)
IL (1) IL142807A0 (zh)
NO (1) NO20012168L (zh)
NZ (1) NZ511465A (zh)
RU (1) RU2246295C2 (zh)
WO (1) WO2000025753A2 (zh)
ZA (1) ZA200103524B (zh)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
CN1325301A (zh) * 1998-11-02 2001-12-05 阿尔扎有限公司 活性物质的控制释放
JP2002534139A (ja) * 1999-01-05 2002-10-15 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜と脈絡膜への経強膜徐放性薬剤標的送達
ES2239065T3 (es) 1999-12-16 2005-09-16 Alza Corporation Formas de dosificacion que presentan una capa barrera frente a la ablacion con laser.
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6616876B1 (en) * 2000-10-03 2003-09-09 Atrium Medical Corporation Method for treating expandable polymer materials
US6923927B2 (en) * 2000-10-03 2005-08-02 Atrium Medical Corporation Method for forming expandable polymers having drugs or agents included therewith
US7396542B2 (en) * 2001-12-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
IL163846A0 (en) 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
ATE401860T1 (de) * 2002-03-29 2008-08-15 Alza Corp Volumensparende arzneiform zur kontrollierten freisetzung
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
DE60326590D1 (de) * 2002-07-29 2009-04-23 Glaxo Group Ltd Tend lamotrigin
AU2003267231A1 (en) * 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AU2003295846A1 (en) * 2002-11-26 2004-06-18 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US20040166160A1 (en) * 2003-01-14 2004-08-26 Ramkumar Subramanian Methods and dosage forms with modified viscosity layers
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
EP1608339B8 (en) 2003-02-28 2012-04-25 McNeill-PPC, Inc. Pharmaceutical co-crystal of celecoxib-nicotinamide
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
CA2540308C (en) 2003-09-26 2013-08-06 Alza Corporation Drug coating providing high drug loading and methods for providing the same
WO2005030182A1 (en) 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
KR20060115860A (ko) * 2003-09-26 2006-11-10 알자 코포레이션 활성 제제의 서방성 전달을 위한 ｏｒｏｓ 푸시-스틱
WO2005030181A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
KR20060130571A (ko) * 2003-10-31 2006-12-19 알자 코포레이션 개선된 흡수를 위한 조성물 및 제형
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20060004037A1 (en) * 2004-03-25 2006-01-05 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US7803786B2 (en) * 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006101584A2 (en) * 2005-03-15 2006-09-28 Diversa Corporation Cellulases, nucleic acids encoding them and methods for making and using them
EP2474308A1 (en) * 2005-06-27 2012-07-11 Valeant International (Barbados) SRL Pharmaceutical formulations containing bupropion hydrobromide
RU2433821C2 (ru) * 2005-08-30 2011-11-20 Пирамал Лайф Сайнсис Лимитед Фармацевтическая композиция метформина с длительным высвобождением и способ ее получения
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20080070990A1 (en) * 2006-05-30 2008-03-20 Stirling Products Limited Use of ractopamine enantiomers
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US20070282010A1 (en) 2006-05-30 2007-12-06 Bridge Pharma, Inc. Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
US20080176955A1 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
CA2678806C (en) * 2007-02-21 2017-05-16 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
JP5572549B2 (ja) 2007-08-13 2014-08-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルコキナーゼの新規な活性化剤
AU2008331928B2 (en) * 2007-12-03 2012-08-16 Bridge Pharma, Inc. Use of RR/SR-ractopamine
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
BRPI0911874A2 (pt) * 2008-04-29 2018-05-22 Pharnext composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
CN102316730A (zh) * 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
PL2799428T3 (pl) 2008-08-13 2017-05-31 Metabasis Therapeutics, Inc. Antagoniści glukagonu
CN101703488B (zh) * 2008-12-16 2013-02-20 北京科信必成医药科技发展有限公司 具有润滑层结构的双层渗透泵控释片及其制备方法
EP2462246B1 (en) 2009-09-28 2017-09-06 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
AU2011237592B2 (en) 2010-04-08 2016-10-27 Emory University Substituted androst-4-ene diones
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
US9102105B2 (en) * 2011-09-13 2015-08-11 Vista Scientific Llc Method for forming an ocular drug delivery device
EP3036226B1 (en) 2013-08-22 2020-01-08 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US11593764B2 (en) * 2015-12-28 2023-02-28 Data Vault Holdings, Inc. Remote medication delivery systems
US11437139B2 (en) 2015-12-28 2022-09-06 Data Vault Holdings, Inc. Method and apparatus for biometric data collection combining visual data with historical health records metadata
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
CA3130379A1 (en) * 2019-03-05 2020-09-10 Kashiv Biosciences, Llc Delayed release methylphenidate compositions
RU2754850C1 (ru) * 2020-07-20 2021-09-08 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Способ определения скорости высвобождения инкапсулированного в ниосомы цефотаксима in vitro

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (zh) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5126142A (en) 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ES2124910T3 (es) * 1993-08-31 1999-02-16 Alza Corp Dispensador que contiene un agente hidrofobo.
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
CN1325301A (zh) * 1998-11-02 2001-12-05 阿尔扎有限公司 活性物质的控制释放

Also Published As

Publication number Publication date
AU1238500A (en) 2000-05-22
KR20010075676A (ko) 2001-08-09
NZ511465A (en) 2003-10-31
NO20012168D0 (no) 2001-05-02
US20050136113A1 (en) 2005-06-23
US6368626B1 (en) 2002-04-09
CN1325301A (zh) 2001-12-05
WO2000025753A2 (en) 2000-05-11
US20020048600A1 (en) 2002-04-25
HUP0104993A3 (en) 2003-02-28
CA2350246A1 (en) 2000-05-11
IL142807A0 (en) 2002-03-10
JP2002528486A (ja) 2002-09-03
HK1039456A1 (zh) 2002-04-26
RU2246295C2 (ru) 2005-02-20
CA2350246C (en) 2010-04-27
HUP0104993A2 (hu) 2002-05-29
EP1652516A2 (en) 2006-05-03
EP1126827A2 (en) 2001-08-29
EP1652516A3 (en) 2006-05-17
US6855334B2 (en) 2005-02-15
NO20012168L (no) 2001-06-13
WO2000025753A3 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
US6368626B1 (en) Controlled delivery of active agents
US6596314B2 (en) Controlled release liquid active agent formulation dosage forms
CA2540059C (en) Controlled release formulations exhibiting an ascending rate of release
WO2006023286A2 (en) Controlled release nanoparticle active agent formulation dosage forms and methods
ZA200603309B (en) Controlled release formulations exhibiting an ascending rate of release
AU710389B2 (en) Uniform drug delivery therapy
EP1653922A2 (en) Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050136108A1 (en) Stepwise delivery of topiramate over prolonged period of time
EP1126853B1 (en) Controlled delivery of antidepressants
US20010031279A1 (en) Controlled delivery of antidepressants
US20030203029A1 (en) Controlled release liquid active agent formulation dosage forms
US6706282B1 (en) Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
MXPA01004371A (en) Controlled delivery of active agents
EP1428535A1 (en) Controlled delivery of antidepressants